PAHC Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 7.29% compared to Phibro Animal Health Corp.'s net margin of 14.91%. Phibro Animal Health Corp.'s return on equity of 24.77% beat Boston Scientific Corp.'s return on equity of 12.46%.

Phibro Animal Health Corp. has a consensus price target of $43.00, signalling upside risk potential of 15%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 30.98%. Given that Boston Scientific Corp. has higher upside potential than Phibro Animal Health Corp., analysts believe Boston Scientific Corp. is more attractive than Phibro Animal Health Corp..

Phibro Animal Health Corp. has a beta of 0.771, which suggesting that the stock is 22.868% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Phibro Animal Health Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 1.28%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health Corp. pays 40.46% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phibro Animal Health Corp. quarterly revenues are $363.9M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Phibro Animal Health Corp.'s net income of $26.5M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Phibro Animal Health Corp.'s price-to-earnings ratio is 22.48x while Boston Scientific Corp.'s PE ratio is 51.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health Corp. is 1.09x versus 7.42x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Masimo Corp. has a net margin of 7.29% compared to Phibro Animal Health Corp.'s net margin of 14.46%. Phibro Animal Health Corp.'s return on equity of 24.77% beat Masimo Corp.'s return on equity of -19.18%.

Phibro Animal Health Corp. has a consensus price target of $43.00, signalling upside risk potential of 15%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 37.26%. Given that Masimo Corp. has higher upside potential than Phibro Animal Health Corp., analysts believe Masimo Corp. is more attractive than Phibro Animal Health Corp..

Phibro Animal Health Corp. has a beta of 0.771, which suggesting that the stock is 22.868% less volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.

Phibro Animal Health Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 1.28%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health Corp. pays 40.46% of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phibro Animal Health Corp. quarterly revenues are $363.9M, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Phibro Animal Health Corp.'s net income of $26.5M is lower than Masimo Corp.'s net income of $53.7M. Notably, Phibro Animal Health Corp.'s price-to-earnings ratio is 22.48x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health Corp. is 1.09x versus 4.23x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 7.29% compared to Phibro Animal Health Corp.'s net margin of 12.4%. Phibro Animal Health Corp.'s return on equity of 24.77% beat Insulet Corp.'s return on equity of 18.92%.

Phibro Animal Health Corp. has a consensus price target of $43.00, signalling upside risk potential of 15%. On the other hand Insulet Corp. has an analysts' consensus of $377.72 which suggests that it could grow by 32.3%. Given that Insulet Corp. has higher upside potential than Phibro Animal Health Corp., analysts believe Insulet Corp. is more attractive than Phibro Animal Health Corp..

Phibro Animal Health Corp. has a beta of 0.771, which suggesting that the stock is 22.868% less volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.428%.

Phibro Animal Health Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 1.28%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health Corp. pays 40.46% of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phibro Animal Health Corp. quarterly revenues are $363.9M, which are smaller than Insulet Corp. quarterly revenues of $706.3M. Phibro Animal Health Corp.'s net income of $26.5M is lower than Insulet Corp.'s net income of $87.6M. Notably, Phibro Animal Health Corp.'s price-to-earnings ratio is 22.48x while Insulet Corp.'s PE ratio is 82.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health Corp. is 1.09x versus 8.19x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

TransMedics Group, Inc. has a net margin of 7.29% compared to Phibro Animal Health Corp.'s net margin of 16.91%. Phibro Animal Health Corp.'s return on equity of 24.77% beat TransMedics Group, Inc.'s return on equity of 33.29%.

Phibro Animal Health Corp. has a consensus price target of $43.00, signalling upside risk potential of 15%. On the other hand TransMedics Group, Inc. has an analysts' consensus of $144.73 which suggests that it could grow by 12.89%. Given that Phibro Animal Health Corp. has higher upside potential than TransMedics Group, Inc., analysts believe Phibro Animal Health Corp. is more attractive than TransMedics Group, Inc..

Phibro Animal Health Corp. has a beta of 0.771, which suggesting that the stock is 22.868% less volatile than S&P 500. In comparison TransMedics Group, Inc. has a beta of 2.061, suggesting its more volatile than the S&P 500 by 106.067%.

Phibro Animal Health Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 1.28%. TransMedics Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phibro Animal Health Corp. pays 40.46% of its earnings as a dividend. TransMedics Group, Inc. pays out -- of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phibro Animal Health Corp. quarterly revenues are $363.9M, which are larger than TransMedics Group, Inc. quarterly revenues of $143.8M. Phibro Animal Health Corp.'s net income of $26.5M is higher than TransMedics Group, Inc.'s net income of $24.3M. Notably, Phibro Animal Health Corp.'s price-to-earnings ratio is 22.48x while TransMedics Group, Inc.'s PE ratio is 51.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phibro Animal Health Corp. is 1.09x versus 8.85x for TransMedics Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.